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AbstrACt
background Acute pancreatitis (AP) is an inflammatory 
condition that can lead to late consequences. Recurrent 
AP (RAP) develops in 20% of patients and chronic 
pancreatitis (CP) occurs in 7%–12.8%. However, we do 
not have sufficient information to establish an evidence-
based statement to define early CP, or how to prevent its 
development.
Aim The aim of this study was to understand the 
influencing factors and to determine which parameters 
should be measured or used as a biomarker to detect 
the early phase of CP.
Methods/Design This is an observational prospective 
follow-up study of the GOULASH-trial (ISRTCN 
63827758) in which (1) all severity of pancreatitis 
are included; (2) patients receive only therapeutic 
modalities which are accepted by the evidence based 
medicine (EBM) guideline; (3) whole blood, serum and 
plasma samples are stored in our biobank; and (4) 
large amount of variables are collected and kept in our 
electronic database including anamnestic data, physical 
examination, laboratory parameters, imaging, therapy 
and complications. Therefore, this fully characterised 
patient cohort are well suitable for this longitudinal 
follow-up study. Patients’ selection: patients enrolled 
in the GOULASH study will be offered to join to the 
longitudinal study. The follow-up will be at 1, 2, 3, 4, 5 
and 6 years after the episode of AP. Anamnestic data 
will be collected by questionnaires: (1) diet history 
questionnaire, (2) 36-Item Short-Form Health Survey, 
(3) physical activity questionnaire and (4) stress 
questionnaire. Genetic tests will be performed for the 
genes associated with CP. The exocrine and endocrine 
pancreatic, liver and kidney functions will be determined 
by laboratory tests, stool sample analyses and imaging. 
Cost-effectiveness will be analysed to examine the 
relationship between events of interest and health-
related quality of life or to explore subgroup differences.
Conclusion This study will provide information about 
the risk and influencing factors leading to CP and 
identify the most useful measurable parameters.
trial registration number ISRCTN63396106
bACkgrounD
Acute pancreatitis (AP) is a severe inflam-
matory condition with possible late compli-
cations.1 Twenty per cent of patients with 
AP tend to develop recurrent acute pancre-
atitis (RAP),2 and in 7%–12.8%  of patients, 
chronic pancreatitis (CP) will occur.3–5 CP 
is an incurable disease; the incidence of CP 
in Western countries is 10–50/100 000 and 
it is more common in men.2 6 It is well docu-
mented that RAP can lead to CP; therefore, 
it might be considered as the early form 
of CP. From the first attack of AP until the 
strengths and limitations of this study
 ► Patients suffering from acute pancreatitis (AP) will 
be followed up at 1, 2, 3, 4, 5 and 6 years after the 
episode of AP. This way the study is able to give 
a more precise, detailed insight of the possible 
development of pancreatitis within a wide time 
frame.
 ► Anamnestic data will be collected by questionnaires 
about dietary habits, physical activity, stress and an-
amnestic data questionnaires, which means plenti-
ful quality data collection with low costs; therefore, 
the study has a satisfactory cost-benefit ratio.
 ► Genetic tests will be performed for deeper level of 
understanding of the genetic background of chronic 
pancreatitis (CP).
 ► Since the leading aetiology of CP is alcohol, several 
subjects may not attend the follow-up appointment 
every year.
 ► Considering that CP will be assessed on a year-
ly basis, we will have no exact date when the CP 
developed.
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end-stage CP, there is a long period; however, there is 
no information about the characteristic of the road, 
or how the CP will be formed from the first attack. Risk 
factors leading to CP or influencing the development of 
CP are not well characterised yet.
CP represents a chronic inflammatory state of the 
pancreas which is caused by regular alcohol consump-
tion, smoking, hypercalcaemia and genetic factors.7 
Alcohol consumption is the most common risk factor,8 9 
which increases the risk logarithmically.10 11 The Harmo-
nizing diagnosis and treatment of chronic pancreatitis 
across Europe (HaPanEu) guideline highlights that 
smoking is an independent risk factor which may worsen 
the prognosis of CP.11 CP is most commonly diagnosed 
at late stages based on morphological changes; fibrosis 
can be observed and exocrine insufficiency is present, 
which means a pancreatic burnout with more than 90% 
loss of the healthy pancreatic tissue.12 Whitcomb formu-
lated the definition of the early phase of CP but the 
parameters that could indicate the diagnosis are not 
well characterised.13 Yamabe et al highlighted in a review 
that the screening of patients for suspicion of early CP 
and the treatment of early CP are very important from 
both the patients’ and the healthcare economics’ point 
of view.14
An important feature of CP is pancreatic exocrine 
insufficiency (PEI), which leads to the deterioration of 
the nutritional status and worsen the quality of life of 
patients without treatment and follow-up.15 PEI is also a 
risk factor for increased mortality in patients with CP.16 
Because of the fat malabsorption, steatorrhea will occur 
and measuring faecal elastase-1 level provides indirect 
information on exocrine pancreatic insufficiency.16 The 
gold standard treatment of PEI is pancreatic enzyme 
replacement therapy, which helps to avoid malnutri-
tion and improves the nutritional status of patients with 
CP17 18; therefore, patients with high risk for CP need to 
be  followed and therapy should be initiated as early as 
possible.
Pancreatic endocrine insufficiency develops more 
frequently after severe AP and its severity is directly asso-
ciated with the extent of pancreatic necrosis,19 and it is 
defined as type 3c diabetes or pancreatogenic diabetes. 
In pancreatogenic diabetes, both insulin production 
and glucagon secretion are impaired.20 The impor-
tance of the topic is confirmed by the recently devel-
oped prediabetes self-assessment screening score after 
acute pancreatitis (PERSEUS) score, which helps to 
identify individuals who are at high risk for developing 
new-onset diabetes after an episode of AP.21
Most patients with CP are suffering from recurrent 
episodes of pain, which usually cannot be eliminated by 
conservative treatment. Based on the step-up approach, 
endoscopic interventions are given prior to surgery, but 
a meta-analysis showed that early surgery is associated 
with increased likelihood of complete postoperative 
pain relief, reduced risk of pancreatic insufficiency and 
the need for further intervention.22
Cost-effectiveness analysis is the evaluation of the 
joint distribution of differences in cost and clinical 
effect and has a very important role in chronic diseases. 
It provides an early opportunity to produce reliable esti-
mates of cost-effectiveness at low marginal cost. Access 
to individual patient data also permits a wide range of 
statistical and econometric techniques to examine the 
relationship between events of interest and health-re-
lated quality of life or to explore subgroup differences.
Several studies analysed the changes in laboratory 
parameters in CP. The concentration of leptin23 was 
significantly lower in the serum samples of patients 
with CP compared with controls, while interleukin (IL) 
1β, IL-6, IL-8 and tumour necrosis factor α (TNF-α) 
showed elevated levels.24 A review summarised the 
measurable parameters of the beta cell function, which 
can also be used in the diagnosis.25
Genetics plays an important role in the development 
of CP. As CP often evolves through recurrent attacks 
of AP, in our study we aim to investigate the effect of 
genetic risk factors on the disease onset and progres-
sion. Over the past two decades, it has been demon-
strated that premature trypsinogen activation plays a 
central pathogenic role in the development of CP.26 
Moreover, an alternative pathomechanism unrelated to 
accelerated intrapancreatic trypsinogen activation has 
been identified, in which mutation-induced misfolding 
and consequent endoplasmic reticulum stress lead to 
acinar cell damage and pancreatitis.26
AiMs AnD objeCtives
GOULASH PLUS is an observational prospective 
follow-up study of the individuals enrolled in the 
GOULASH trial27 (http://www. pancreas. hu/ en/ 
studies/ goulash, ISRTCN 63827758) in which (1) 
all severity of pancreatitis are included; (2) patients 
receive only therapeutic modalities which are part of 
the evidence-based guideline; (3) whole blood, serum 
and plasma samples of the enrolled individuals are 
stored in our biobank; and (4) a large number of vari-
ables are collected and kept in our electronic data-
base, including medical and family history, findings of 
physical examination, laboratory parameters, results 
of diagnostic imaging and detailed data on therapy 
and complications. Therefore, the fully characterised 
patient cohort of the GOULASH trial is ideal for this 
longitudinal follow-up study.
Our aim is to understand the course of AP leading to 
CP and to find the factors that can protect the pancreas 
from the development of the disease. We will follow 
the most important factors in our subjects' structure, 
aiming to find protective factors and the first predictable 
parameters of the disease. The study will provide results, 
which will help to understand the development and risk 
factors of late complications in AP and the development 
of the pancreatic damage.
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MethoDs
study design
GOULASH PLUS is a 6-year observational prospective 
follow-up study with no intervention. Patients suffering 
from AP, who took part in the GOULASH study, will be 
approached and enrolled if consent is given. Participants 
will be followed up in 1, 2, 3, 4, 5 and 6 years following 
their discharge after the admission with AP. The follow-up 
visits will be arranged every 12 months (±1 month) for 6 
years. After receiving detailed verbal and written infor-
mation on the study, the consent form will be signed. If 
consent is given, the following tests and investigations will 
be arranged at each follow-up, and we collect the informa-
tion under the same code as used in the GOULASH study 
completed with P and the number of the year of the 
follow-up to avoid the contravention of personal rights.
To detect the earliest morphological changes and 
late complications of AP, transabdominal ultrasonog-
raphy (US) (1, 3, 5 years) and in the second, fourth and 
sixth year endoscopic ultrasonography (EUS) examina-
tion will be performed (figure 2). The transabdominal 
US is part of the standard work-up for patients with 
AP28; however, several studies explored the visualisation 
of morphological changes in CP by the transabdom-
inal US and reported varying diagnostic accuracy with 
a sensitivity of 70%–80%.29 30 One large study reported 
sensitivities for US >85% for the features calcifications, 
pancreatic duct dilations and cysts.30 Generally, EUS will 
be suggested based on the HaPanEU guideline’s 2–9 
point.11 It is the most sensitive imaging technique in the 
early phase of CP, but if the participant disagrees, MRI 
will be performed for increasing the attendance on the 
controls. A recent meta-analysis31 showed that the sensi-
tivity of EUS and magnetic resonance cholangiopacrea-
tography (MRCP) are 81% and 78%, respectively, while 
the specificity was 90% and 96%, respectively. The radiol-
ogist may indicate a CT, EUS or MRI examination if the 
pancreas is not visualisable, uncertain features of CP on 
the US scan, suspicion of focal lesions or any novum alter-
ations in the pancreas. Blood samples will be collected for 
laboratory analysis and stored in biobank for later testing. 
Oral glucose tolerance test (OGTT) will be performed 
when diabetes mellitus (DM) is unknown, and fasting 
plasma glucose (FPG) level is ≤7 mmol/L. In this trial, 
we will be guided by the diagnostic criteria of DM and 
prediabetic states, which were defined by the WHO in 
1999.8 Homeostasis model assessment of β-cell function 
(HOMA-Beta) will be calculated based on 20×Insulin/
Glucose-3.5 equation in percentage.25 Patients will be 
given a stool sample collection kit and they will be asked 
to provide a sample for the measurement of faecal elastase 
level, which is the most widely employed non-invasive test 
to document EPI. Faecal elastase is widely available and 
can be performed while the patient is taking commercial 
pancreatic enzyme replacement therapy (PERT) prod-
ucts. The interpretation of faecal elastase test will be made 
based on normal pancreatic function 200–500 µg/g, mild 
pancreatic dysfunction 100–199 µg/g and severe pancreas 
exocrine insufficiency <100 µg/g. For the detailed assess-
ment of the participants’ diet, the validated Diet History 
Questionnaire (DHQ) will be completed (table 1, online 
supplementary file 1). Pain, environmental factors such as 
alcohol consumption and smoking, physical activity and 
quality of life will be detected by validated questionnaires. 
To collect detailed information on the quality of life and 
pain, 36-Item Short-Form Health Survey (SF-36) ques-
tionnaire will be used (table 1, online supplementary file 
1). The questionnaire will be completed with the help of 
a  clinical research administrator; therefore, improperly 
completed datasheets and incorrect data upload will be 
avoided and controlled.
The diagnosis of CP is based on clinical (weight loss, 
malnutrition, diarrhoea), morphological (imaging) 
and functional parameters (pancreatic function 
tests).8 11 32 The diagnosis will be based, at EUS examina-
tion, on morphological changes according to Rosemont 
criteria33 (online supplementary file 2), on the presence 
of pancreatic ductal calcifications examined by US and 
CT, and pancreatic duct abnormalities investigated by 
MRCP.11
Whenever these alterations have been diagnosed, CP 
is already developed; in this study, the early phase of CP 
will be investigated in the 2-year period before the CP 
retrospectively.
Table 1 Schedule of fulfilled questionnaires during the follow-up period
Title Source
Physical and 
socioeconomic status
American Community Survey (ACS); The MacArthur Scale of Subjective Social Status 
(Supplementary document 1 page 11–12)
Details from the medical 
history
Acute Pancreatitis Questionnaire (Registry for Pancreatic Patients by Hungarian Pancreatic Study 
Group) (Supplementary document 1 page 1–10)
Dietary habits Diet History Questionnaire, V.2.0. National Institutes of Health, Epidemiology and Genomics 
Research Program, National Cancer Institute. 2010. (Supplementary document 1 page 28–68)
Physical activity International Physical Activity Questionnaire (IPAQ) (long, usual week version) (Supplementary 
document 1 page 13–17)
Stress Perceived Stress Scale (10-item version) (Supplementary document 1 page 17–18)
Quality of life, pain RAND 36-Item Health Survey (Version 1.0) (SF-36)30 (Supplementary document 1 page 22–27)
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Genetic testing of participants will be performed in 
the most important genes for AP and CP, such as PRSS1, 
CPA1, SPINK1, CTRC and CFTR genes.34 In all patients 
enrolled in the GOULASH PLUS study, we will analyse 
the known susceptibility genes associated with CP in 
both the trypsin-dependent and misfolding patholog-
ical pathways: PRSS1, SPINK1, CTRC and CPA1. In addi-
tion, we will also investigate CFTR, as certain mutations 
of this gene may modify pancreatitis risk.35 A control 
cohort of healthy blood donors from the Hungarian 
National Pancreas Registry will also be analysed to 
determine the carrier frequency of different variants in 
this population.
The University of Pécs Medical School will be the 
leading centre of the study and several laboratory param-
eters and genetic samples will be measured and processed 
here. The facilities of the biobank are also located at the 
University of Pécs Institute for Translational Medicine. The 
following partners already participate in the GOULASH 
study: University of Debrecen (Dr Mária Papp), Univer-
sity of Szeged (Dr László Czakó) and hospitals of Gyula 
(Dr János Novák) and Székesfehérvár (Dr Ferenc Izbéki). 
The GOULASH PLUS study is open for centres who take 
part in the GOULASH study.
Duration
The pilot part of the GOULASH PLUS study started 
at 1 February 2018 (one year after the first patient was 
involved in GOULASH study and discharged from the 
hospital). The estimated date of finishing the study is 
28 February 2025.
Cost-effectiveness analysis
Cost-effectiveness analysis is about the evaluation of the 
joint distribution of differences in cost and clinical effect. 
It provides an early opportunity to produce reliable esti-
mates of cost-effectiveness at low marginal cost. Access 
to individual patient data also permits a wide range of 
statistical and econometric techniques, to examine the 
relationship between events of interest and health-related 
quality of life or to explore subgroup differences. For this 
purpose along with the clinical outcome measures, we 
should also gather information about the quality of life 
of patients and the resource use and unit cost of interven-
tion and treatments used (table 2).
The categories of resource use that are included in 
the study were determined according to the perspec-
tive of the payer. This perspective usually includes direct 
medical care, including the intervention itself, treatment 
of any side effects or complications, and follow-up care to 
the intervention or the underlying condition, which in 
this case is complemented with a payment for sick leave, 
which is an indirect cost.
Additional information will be required from the patient 
questionnaire and from the database of the National 
Health Insurance Fund Administration (NHIFA) and 
Central Administration of National Pension Insurance.
examined parameters
The following parameters will be measured or collected 
at 1, 2, 3, 4, 5 and 6 years control:
1. Laboratory parameters:
a. General: amylase (U/L); lipase (U/L); white cell 
count (G/L); red cell count (T/L); haemoglobin 
(g/L); haematocrit (%); thrombocyte (G/L); C-re-
active protein (mg/L); creatinine (µmol/L), carb-
amid (mmol/L); serum bilirubin (µmol/L); GGT 
(mmol/L); GOT (mmol/L); GPT (mmol/L); ALP 
(mmol/L); uric acid (mmol/L); cholesterol (HDL, 
LDL) (mmol/L); triglycerides (mmol/L); serum 
protein (g/L); albumin (g/L).
b. Endocrine: C-peptide* (pmol/L); HgbA1C (%); 
OGTT test glucose (mmol/L) and insulin level 
(pmol/L) at 0, 60 and 120 min.
c. Exocrine: Faecal elastase test*.
2. Biobank: (a) plasma; (b) serum; (c) stool for later 
analysis
a. Leptin* (pmol/L); IL-1β* (pmol/L); IL-6* 
(pmol/L); TNF-α* (pmol/L); somatostatin* 
(pmol/L); pancreatic polypeptide* (pmol/L); 
amylin* (pmol/L); glucagon* (pmol/L); *signed 
parameters will be measured at our centre if there is 
no possibility in the smaller centres.
3. Information about (b) smoking; (c) alcohol; (d) 
drugs; (e) complains: pain and quality of life—MOS 
36-Item Short-Form Health Survey (SF-36); (f) dietary 
fat intake—DHQ questionnaire; (g) body weight, body 
mass index (BMI).
4. Genetic: PRSS1, CPA1, SPINK1, CTRC and CFTR.
Primary eendpoint
The primary endpoint was the development of chronic 
pancreatitis based on morphological changes and clinical 
signs.
Table 2 Evaluation of planned categories for cost-
effectiveness analysis. ER, emergency room; GP, general 
practitioner; NHIFA, National Health Insurance Fund 
Administration.
Domain name Source of data
Health outcomes
  Mortality Civil registration database
Resource utilisation during follow-up period (after discharge)
  GP utilisation NHIFA database
  Outpatient care utilisation NHIFA database
  ER utilisation NHIFA database
  Hospital readmission NHIFA database
  Drug utilisation NHIFA database
Indirect cost
  Sick leave Central Administration of 
National Pension Insurance
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Secondary endpoints
Secondary endpoints include (1) recurrent AP based on 
the International Association of Pancreatology/American 
Pancreatic Association (IAP/APA) guideline’s 2 out of 3 
rule: (a) upper abdominal pain; (b) serum amylase or 
lipase level more than three times than the upper limit of 
a normal range; (c) distinctive pancreatic findings on US 
or CT imaging; (2) exocrine pancreatic insufficiency—
faecal elastase test; (3) endocrine pancreatic insufficiency 
(based on laboratory test, OGTT and FPG); (4) need for 
radiological/surgical interventions—medical records; 
(5) dietary intake assessment—DHQ; (6) quality of life, 
stress, physical activity questionnaires; (7) pain question-
naires; (8) development of pancreas tumour—medical 
records; (9) laboratory parameters—inflammatory cyto-
kines, pancreatic peptides and so on (table 1).
the trial organisation, committees and boards
The coordinator and designer of the GOULASH PLUS 
study are the Centre for Translational Medicine at the 
University of Pécs Medical School (coordinating institu-
tion and sponsor) and the Hungarian Pancreatic Study 
Group (HPSG-coordinating society). The HPSG was 
established in 2011 to stimulate research in pancreatic 
diseases.
The following committees and boards will be involved:
Steering Committee (SC): The committee will be led by 
PH (corresponding and principal investigator, a gastroen-
terologist and internal medicine specialist).
The members in Szeged will be LC (gastroenterol-
ogist); Debrecen: MP (gastroenterologist); Pécs: ÁV 
(gastroenterologist), ON (endocrinologist), BB (endo-
crinologist), NF (radiologist), OF (radiologist), RP 
(surgeon), DK (surgeon); Székesfehérvár: FI (gastro-
enterologist); Gyula: JN (gastroenterologist) and one 
member of each joined institution. AM is a principal 
organiser, KM is a trial management specialist, whereas 
AS leads the multidisciplinary core facility which will assist 
the scientists to run the study successfully.
The SC will make decisions concerning all relevant 
questions including dropouts during the study.
International Translational Advisory Board (ITAB): 
The board will consist of a gastroenterologist (MML), a 
surgeon and two basic scientists (JPN, MST, OHP).
The ITAB will continuously monitor the progress of the 
study and will advise the SC.
The study was designed by the SC and ITAB. It was 
funded by the University of Pécs, Medical School. The 
sponsor was not involved in the design of the study and 
will have no access to the database or the randomisation 
code. The study also contains an independent physician 
and safety manager.
study population
All patients enrolled in the GOULASH study will be 
offered the opportunity to participate in the GOULASH 
PLUS study. They will be given detailed verbal and written 
information by clinical doctors and administrators. 
After the consent is given, the annual follow-ups will be 
arranged and the above-detailed tests (table 1) and inves-
tigations will be performed (figures 1 and 2).
Figure 1 Flow chart of participants in the GOULASH PLUS study. CP, chronic pancreatitis;  EUS, endoscopic ultrasonography; 
OGTT, oral glucose tolerance test; US, ultrasonography.
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Inclusion criteria for GOULASH study
The inclusion criteria are as follows: (1) patients above 
18 years, (2) diagnosed AP based on the ‘2 out of 3’ 
rules of IAP/APA guideline36: (a) upper abdominal 
pain,(b) serum amylase or lipase >3× upper limit of 
normal range and (c) characteristic findings on pancre-
atic imaging; however, those patients without abdominal 
pain will be excluded because the onset of AP cannot be 
assessed; (3) written informed consent form is signed.
Exclusion criteria or reasons of compulsory dropout for the 
GOULASH study
The exclusion criteria are as follows: (1) hospital-
isation 72 hours before admission; (2) abdominal 
pain >120 hours (5 days); (3) delirium tremens; (4) 
Child-Pugh C stage liver cirrhosis; (5) AP due to malig-
nancy; (6) already on artificial nutrition (Enteral 
nutrition (EN) or parenteral nutrition (PN)); (7) preg-
nancy; (8) BMI above 40 or below 18; (9) age above 80; 
(10) ketoacidosis; (11) whenever CT with contrast is 
contraindicated.
Inclusion criteria for GOULASH PLUS
Patients participated in the GOULASH study and signed 
the consent form.
Exclusion criteria for GOULASH PLUS
The patient does not sign the consent form, or the patient 
withdraws the consent.
According to the ethical laws, individuals can leave the 
study at any time without reason and explanation. Serious 
medical reasons not related to pancreatitis (ie, accidents, 
stroke) means withdrawal of the subject from the study. 
All withdrawals will be filled; moreover, there will be no 
replacement of individual subjects after withdrawal.
sample size
Sample size calculation for the GOULASH study was based 
on data extracted from the Hungarian National Registry 
of AP operated by the HPSG. The calculated sample size 
of the GOULASH study is 957 participants; however, the 
sample size calculation for the GOULASH PLUS study was 
performed based on the data of the HPSG registry and the 
articles published by Yadav et al5 and Kin et al.37 Seventy-five 
newly developed CP is necessary to reach the required 
5% alpha and 80% power for the individual biomarkers. 
Literature data suggest that the chance to develop CP 
is around 13% within the 6-year period. Therefore, the 
GOULAS-PLUS study requires 577 patients involvement. 
Several biomarkers including laboratory and imaging 
parameters, 2 years prior to the development of CP, will 
be investigated. Based on the preliminary data concerning 
Figure 2 Shows the schedule of enrolment and assessments of participants according to the SPIRIT 2013 guideline. *A total 
of 957 patients participated in the GOULASH study. **The Administrator will call the patient’s attention to follow-up visits by 
telephone. ***Based on the preliminary data concerning the compliance with the 1-month follow-up, we estimate dropouts and 
participants who do not sign the consent form. ****Oral glucose tolerance test  (OGTT) will be performed if diabetes mellitus 
is unknown and the fasting plasma glucose is level is ≤7 mmol/L. *****Based on morphological changes, the radiologist may 
recommend CT, endoscopic ultrasonography or MRI examination. ******In the University of Pécs, samples in the biobank will 
be kept to measure any kind of possible biomarkers which could be a candidate in the diagnosis of early phase of chronic 
pancreatitis. *******The questionnaires will be completed by the clinical research administrators. ******** It will be performed in the 
University of Pécs and Szeged.
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the compliance with the 1 month follow-up, we estimate 
that 80% of the GOULASH study cohort will take part in 
the GOULASH PLUS study. However, we expect that the 
number of patients will decrease every year due to multiple 
reasons such as loss of motivation, migration and other 
reasons independent of AP (ageing, comorbidity).
Pitfalls: If the number of participants from the GOULASH 
study is low, patients with AP who were not included the 
GOULASH study will be approached too. However, in that 
case, the same inclusion criteria are kept, which are written 
in the GOULASH protocol.
Data management and statistical probes
Data handling
Data will be handled by Data Management and Biostatis-
tics provider Organisation of the Centre for Translational 
Medicine. Electronic case report form (eCRF) will be used. 
The investigator will ensure that the data in the eCRF are 
accurate, complete and legible. Detailed data flow will 
be described in the data management plan. Any missing, 
impossible or inconsistent recordings in the eCRFs will be 
referred back to the investigator using a data query form, 
and be documented for each individual subject before 
clean file status is declared.
Study populations
Two analysis populations will be defined: (1) the safety 
analysis set consists of all patients enrolled to the study; (2) 
per protocol set with all enrolled patients who finished the 
study conforming to the requirements of the study protocol.
Applied software
Statistical analysis will be performed using SAS V.9.2 or 
SPSS V.24 statistical packages; Microsoft MS Word 2010 will 
be used for reporting.
Statistical methods
Baseline patient and disease characteristics will be anal-
ysed using descriptive analysis. Demographic and baseline 
characteristics will be summarised for the overall study 
population. Continuous variables will be described by 
mean, median, SD and ranges, and categorical variables will 
be described by absolute and relative frequencies. A graph-
ical presentation of efficacy variables will be prepared, if 
applicable.
Descriptive statistics for the followed parameters will be 
analysed. Mean changes (and their 95% CI) from baseline 
to end-of-study visit will be presented as well. χ2 tests will 
be applied to compare proportions between the different 
groups. Mortality will be investigated using the Kaplan-
Meier survival analysis method, while subgroup compari-
sons will be performed using the χ2 or Fisher’s exact test, 
as appropriate.
Subgroups
The following subgroups will be made during statistical 
analyses: (1) ages (under 40, 40–60, 60–80, above 80 years); 
(2) BMI (below 20, 20–25, 25–30, 30–35, above 35); (3) the 
number of RAP, CP; (4) severity of the disease SAP (severe 
AP) and MAP (mild and moderately severe AP).
All subgroup analyses will be done descriptively. No 
confirmatory statistical testing will be applied. Hence, statis-
tical tests and the p values attached to them will be regarded 
as descriptive and not as tests of hypotheses.
Details of the applied statistical tests will be described in 
the statistical analysis plan.
Patient and public involvement statement
The GOULASH PLUS study aims to detect the first signs 
and biomarkers of early CP. It will be a 6-year observational 
prospective follow-up study with no intervention. The study 
will provide results, which will help to understand the 
development and risk factors of late complications in AP 
and the development of the pancreatic damage. All patients 
enrolled in the GOULASH study will be offered the oppor-
tunity to participate in the GOULASH PLUS study. They 
will be given detailed verbal and written information by clin-
ical doctors and administrators. We would like to publish 
the results in one of the internationally highly recognised 
journals.
PubliCAtion PoliCy
Centres providing more than 25 patients can provide two 
authors to the author's list. Every additional 25 patients will 
give the opportunity to nominate an author.
DisCussion
expected results
We aim to understand the development and natural history 
of CP at its early phase. We would like to identify factors that 
are associated with the development of CP. With the help of 
the new information, new pharmaceutical or lifestyle inter-
ventions could be recognised. Our aim was to publish our 
future data in a high ranking multidisciplinary or gastro-
enterology journal, which of course will largely depend on 
the outcome of the study. We have done all the necessary 
administrative duties, which are compulsory for such distin-
guished clinical journals.
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